Abstract CT010: Phase I trial combining the PARP inhibitor olaparib (Ola) and AKT inhibitor AZD5363 (AZD) in germline (g)BRCA and non-BRCA mutant (m) advanced cancer patients (pts) incorporating noninvasive monitoring of cancer mutations

No abstract is available for this paper.

• Publication year

  2016

• Venue

  Cancer Research

• Publication date

  2016-07-15

• Fields of study

  Medicine

• Identifiers
  DOI 10.1158/1538-7445.AM2016-CT010
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• No references are available for this paper.

• Targeting the PI3K pathway and DNA damage response as a therapeutic strategy in ovarian cancer.

  2020cites this paper
• Olaparib for advanced breast cancer.

  2020cites this paper
• The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas.

  2019cites this paper
• State-of-the-art strategies for targeting the DNA damage response in cancer

  2018cites this paper
• Update on PARP Inhibitors in Breast Cancer

  2018cites this paper
• Olaparib for the treatment of breast cancer

  2018cites this paper
• The Pathway in Human Disease.

  2017cites this paper
• The PI3K Pathway in Human Disease.

  2017cites this paper
• Maximising the potential of AKT inhibitors as anti‐cancer treatments

  2017cites this paper
• Olaparib for the treatment of breast cancer

  2017cites this paper
• Targeting DNA Repair in Cancer: Beyond PARP Inhibitors.

  2017cites this paper
• PARP inhibition in BRCA2-mutated prostate cancer.

  2016cites this paper
• Breast Cancer ( ML Telli , Section Editor ) Update on PARP Inhibitors in Breast Cancer

  year unknowncites this paper